Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The study drug, Aprepitant, is currently used to control chemotherapy induced nausea and vomiting and is also approved for post-operative nausea and vomiting. The investigators' evaluation of it in morbidly obese patients will demonstrate its ability to control nausea and vomiting post-operatively in this subset of patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Treatments: Aprepitant; Fosaprepitant

Criteria

Inclusion Criteria:

Subjects included in this study must be:

• Female

• At least 18 years of age

• Non-smoking

• At high risk for PONV

• Obese with a BMI of at least 45 kg/m2

• Undergoing upper gastrointestinal surgery requiring postoperative opioid analgesia

Exclusion Criteria:

Subjects will be excluded if:

• They have a known allergy to Aprepitant or Ondansetron

• They are currently taking Orap (pimozide), Seldane (terfenadine), Hismanal (astemizole), or Propulsid (cisapride)

• They are pregnant

• They are breastfeeding

• They plan on getting pregnant in the 2 months following surgery

• They are not able to receive patient controlled analgesia (PCA) following surgery

• They have a known drug or alcohol abuse problem

• They have chronic nausea and vomiting